VRNA — Verona Pharma Share Price
0.000.00%
Last trade - 00:00- $8.99bn
- $8.83bn
- $42.28m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 66.1 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 39.66 | ||
| Price to Tang. Book | 39.75 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 75.81 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -30.21% | ||
| Return on Equity | -72.61% | ||
| Operating Margin | -119.63% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 40 | 0.46 | n/a | 42.28 | 413.09 | 733.46 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +342.77 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Verona Pharma plc is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of chronic respiratory diseases with unmet medical needs. Ohtuvayre (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD) that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. The Company has evaluated nebulized Ohtuvayre in its Phase III clinical program ENHANCE (Ensifentrine as an Inhaled Nebulized COPD therapy) for COPD maintenance treatment. It has developed formulations of ensifentrine for the three inhalation devices: nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). Ensifentrine has potential in other respiratory diseases such as non-cystic fibrosis bronchiectasis. The Company's subsidiaries include Verona Pharma, Inc. and Verona Pharma Ireland Limited.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- February 24th, 2005
- Public Since
- March 30th, 2005
- No. of Employees
- 209
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 681,056,022
- Address
- Riverside, 3 More London Place, LONDON, SE1 2RE
- Web
- https://www.veronapharma.com/
- Phone
- +44 2032834200
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for VRNA
Similar to VRNA
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Aurinia Pharmaceuticals
NASDAQ Global Market
FAQ
What is the Verona Pharma share price?
As of Today at 23:57 UTC, shares in Verona Pharma are trading at $105.56. This share price information is delayed by 15 minutes.
How has the Verona Pharma share price performed this year?
Shares in Verona Pharma last closed at $105.56 and the price had moved by +290.24% over the past 365 days. In terms of relative price strength the Verona Pharma share price has outperformed the S&P500 Index by +240.02% over the past year.
What are the analyst and broker recommendations for Verona Pharma?
The overall consensus recommendation for Verona Pharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Verona Pharma dividend yield?
Verona Pharma does not currently pay a dividend.
Does Verona Pharma pay a dividend?
Verona Pharma does not currently pay a dividend.
When does Verona Pharma next pay dividends?
Verona Pharma does not currently pay a dividend.
How do I buy Verona Pharma shares?
To buy shares in Verona Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Verona Pharma?
As of the previous close price of $105.56, shares in Verona Pharma had a market capitalisation of $8.99bn.
Where are Verona Pharma shares listed?
Here are the trading details for Verona Pharma:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: VRNA
What kind of share is Verona Pharma?
Based on an overall assessment of its quality, value and momentum Verona Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Verona Pharma share price forecast for 2025?
The analyst consensus target price for shares in Verona Pharma is $106.30. That is 0.7% above the last closing price of $105.56.
Analysts covering Verona Pharma currently have a consensus Earnings Per Share (EPS) forecast of $0.50 for the next financial year.
Find out moreWhat is the trend in the Verona Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Verona Pharma. Over the past six months, its share price has outperformed the S&P500 Index by +43.71%.
As of the last closing price of $105.56, shares in Verona Pharma were trading +54.01% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Verona Pharma PE Ratio?
The Verona Pharma PE ratio based on its reported earnings over the past 12 months is 66.1. The shares last closed at $105.56.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Verona Pharma?
We do not have data on Verona Pharma's directors